Nivolumab

Nivolumab
Fab fragment of nivolumab (blue) binding the extracellular domain of PD-1 (purple). From PDB entry 5ggr.
Antibodi monoklonal
JenisWhole antibody
SumberTemplat:Infobox drug/mab source
TargetPD-1
Data klinis
Nama dagangOpdivo
Nama lainONO-4538, BMS-936558, MDX1106
AHFS/Drugs.commonograph
MedlinePlusa614056
License data
Kategori
kehamilan
  • Use is not recommended
Rute
pemberian		Intravenous (IV)
Kelas obatImmunotherapy[2]
Status hukum
Status hukum
Data sifat kimia dan fisik
RumusC6362H9862N1712O1995S42
Massa molar143.599,39 g·mol−1

Nivolumab adalah obat yang digunakan untuk mengatasi beberapa penyakit kanker.[3] Penggunaan obat Ini untuk kondisi seperti: melanoma, kanker paru-paru, karsinoma sel ginjal, limfoma Hodgkin, kanker kepala dan leher, kanker usus besar, dan kanker hati.[3] Obat ini digunakan melalui penyuntikan perlahan ke dalam pembuluh darah.[3]

Efek samping minor penggunaan obat ini meliputi rasa lelah, ruam, gangguan hati, nyeri otot, dan batuk.[3] Efek samping yang mayor penggunaan obat ini seperti: gangguan pada paru-paru, gangguan pada usus, gangguan fungsi hati, gangguan ginjal, masalah kulit, atau endokrin yang berhubungan dengan sistem kekebalan tubuh.[3] Nivolumab tidak direkomendasikan untuk ibu hamil dan ibu menyusui.[3] Nivolumab merupkan antibodi monoklonal IgG4 manusia yang bekerja untuk memblokir PD-1.[3] Nivolumab merupakan imunoterapi, mekanisme kerja obat ini menghambat titik kontrol, memblokir sinyal yang menghambat aktivasi sel T untuk menyerang sel kanker.[3][2]

Obat ini disetujui untuk penggunaan secara medis di Amerika Serikat pada tahun 2014.[3][4] Nivolumab termasuk dalam Daftar Obat Esensial Organisasi Kesehatan Dunia.[5]

Referensi

  1. ^ "Nivolumab (Opdivo) Use During Pregnancy". Drugs.com. 4 November 2019. Diarsipkan dari versi aslinya tanggal 30 December 2019. Diakses tanggal 11 March 2020. Diarsipkan 30 December 2019 di Wayback Machine.
  2. ^ a b "Nivolumab (Opdivo) | Cancer information | Cancer Research UK". www.cancerresearchuk.org. Diarsipkan dari versi aslinya tanggal 16 December 2019. Diakses tanggal 15 December 2019.
  3. ^ a b c d e f g h i "Nivolumab Monograph for Professionals". Drugs.com. Diarsipkan dari versi aslinya tanggal 30 December 2019. Diakses tanggal 14 November 2019.
  4. ^ "Opdivo- nivolumab injection". DailyMed. 17 December 2019. Diarsipkan dari versi aslinya tanggal 29 October 2020. Diakses tanggal 11 March 2020.
  5. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

Pranala luar

  • "Nivolumab". NCI Drug Dictionary. National Cancer Institute.
  • "Nivolumab". National Cancer Institute. 7 January 2015.
  • Nomor uji klinis NCT01721746 for "A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)" di ClinicalTrials.gov
  • Nomor uji klinis NCT01721772 for "Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma (CheckMate 066)" di ClinicalTrials.gov
  • Nomor uji klinis NCT01844505 for "Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)" di ClinicalTrials.gov
  • Nomor uji klinis NCT02388906 for "Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)" di ClinicalTrials.gov
  • Nomor uji klinis NCT02477826 for "An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)" di ClinicalTrials.gov
  • Nomor uji klinis NCT03215706 for "A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA)" di ClinicalTrials.gov
  • Nomor uji klinis NCT01642004 for "Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)" di ClinicalTrials.gov
  • Nomor uji klinis NCT01673867 for "Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate057)" di ClinicalTrials.gov
  • Nomor uji klinis NCT02899299 for "Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743)" di ClinicalTrials.gov
  • Nomor uji klinis NCT02231749 for "Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)" di ClinicalTrials.gov
  • Nomor uji klinis NCT03141177 for "A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER)" di ClinicalTrials.gov
  • Nomor uji klinis NCT01668784 for "Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)" di ClinicalTrials.gov
  • Nomor uji klinis NCT02181738 for "Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) (CheckMate 205)" di ClinicalTrials.gov
  • Nomor uji klinis NCT01592370 for "An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma" di ClinicalTrials.gov
  • Nomor uji klinis NCT02105636 for "Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)" di ClinicalTrials.gov
  • Nomor uji klinis NCT02387996 for "A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer" di ClinicalTrials.gov
  • Nomor uji klinis NCT02060188 for "An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread (CheckMate142)" di ClinicalTrials.gov
  • Nomor uji klinis NCT01658878 for "An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (CheckMate040)" di ClinicalTrials.gov
  • Nomor uji klinis NCT02743494 for "An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577)" di ClinicalTrials.gov
  • Nomor uji klinis NCT02569242 for "Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer" di ClinicalTrials.gov
  • Nomor uji klinis NCT02872116 for "Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649)" di ClinicalTrials.gov
  • Nomor uji klinis NCT02632409 for "An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer (CheckMate 274)" di ClinicalTrials.gov
Ikon rintisan

Artikel bertopik farmakologi ini adalah sebuah rintisan. Anda dapat membantu Wikipedia dengan mengembangkannya.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.
Kembali kehalaman sebelumnya